March 31, 2009

FDA approves Reclast for osteoporosis care

FDA approves Reclast for osteoporosis care
FDA approves Reclast for osteoporosis care
The drug Reclast has just been approved by the Food & Drug Administration for a new purpose: the treatment and prevention of osteoporosis. Specifically, patients expected to be on glucocorticoids, or steroids, for at least 12 months can now use it.
http://www.novartis.com/
Similar Articles

More in Products

HealthLease purchase completed

CFG Capital Markets, the investment banking platform of Capital Funding Group, announced it was an advisor on a $141.7 million portfolio.

Bulk TV & Internet announce partnership

Bulk TV & Internet has become an authorized partner of Mitel, a provider of cloud and premises-based unified communications and collaboration software.

Oak Grove Capital closes line for Brookdale

Oak Grove Capital announced it has closed a $259 Fannie Mae DUS credit facility for Brookdale Senior Living.